Heart Disease and Statin Treatment Options
Dr. Michael Blaha, MD, MPH, Director of Clinical Research for the Prevention of Cardiovascular Disease at Johns Hopkins discusses detecting heart disease, current guidelines, adhering to treatment, and switching statins when a patient is no longer able to adhere to current therapy. LIVALO, a statin commonly used for high cholesterol, offers a Doctor Discussion Guide on its website that can help patients personalize their conversation with their doctor – whether in person or via telehealth – about their statin treatment options.
Michael Blaha, M.D., M.P.H.
Dr. Michael Blaha is currently Professor of Cardiology and Epidemiology and serves as the Director of Clinical Research for the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease. His clinical interest is in the prevention of cardiovascular disease.
After completing his BS in pre-medical studies at Notre Dame, Dr. Blaha graduated from Vanderbilt University, earning both his MD and MPH in clinical epidemiology and biostatistics. He then completed his residency in Internal Medicine at the Osler Medical Housestaff Training Program at Johns Hopkins, followed by a fellowship in Cardiology. Dr. Blaha is the 4th generation of physicians in his family.
Additionally, Dr. Blaha is an Associate Editor for the Journal of Cardiovascular Computed Tomography, Associate Editor for the Diabetes and Cardiometabolic Clinical Community on acc.org and a standing member of the Endocrinologic and Metabolic Drug Advisory Committee (EMDAC) for the FDA. He is also Principal Investigator for the Coronary Artery Calcium Consortium, co-chair of the Cross Cohort Collaboration, and a Principal Investigator for the American Heart Association (AHA) Tobacco Regulation and Addiction Center.
Dr. Blaha has received grant awards from the National Institutes of Health, FDA, AHA, Amgen, and the Aetna Foundation.
In 2018, he received the Dr. Fred Brancati award at Johns Hopkins for excellence in mentoring. He has mentored over 30 trainees and has delivered Grand Rounds lectures at over 10 institutions.
In 2021, he was named to the Clarivate Highly Cited Researcher List (top 0.1% of world researchers).
0 Comments